Table 1 Summary of trials included in the review
Trial name | Trial characteristics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Phase of trial | Anti-EGFR mAb therapy | Treatment line | Background therapy | Bevacizumab in control arm? | ITT, N | RAS status, N (%) of ITT | RAS wt, N (%) | Biomarker analysis | ||
III | Panitumumab | 3rd | BSC | No | 463 | KRAS codons 12, 13, and 61 | 288 (62) | 153 (53) | BRAF, PIK3CA, PTEN, EGFR GCN | |
20050181 [38] | III | Panitumumab | 2nd | FOLFIRI | No | 1186 | KRAS and NRAS exons 2, 3, 4 | 1014 (85) | 421 (42) | BRAF |
20100007 [39] | III | Panitumumab | 2nd | BSC | No | 377 | KRAS and NRAS exons 2, 3, 4 | 377 (100) | 270 (72) | BRAF |
III | Cetuximab | 1st | FOLFIRI | No | 1198 | KRAS exon 2 | 1063 (89) | 666 (63) | BRAF, EGFR | |
OPUS [40] | II | Cetuximab | 1st | FOLFOX4 | No | 337 | KRAS exon 2 | 315 (93) | 179 (57) | BRAF |
PRIME [10] | III | Panitumumab | 1st | FOLFOX4 | No | 1183 | KRAS and NRAS exons 2, 3, 4 | 1060 (90) | 512 (48) | BRAF |
III | Cetuximab | 2nd | BSC | No | 572 | KRAS exon 2 | 394 (69) | 230 (58) | BRAF, PIK3CA, PTEN, EREG | |
III | Cetuximab | 1st | FOLFOX4 | No | 393 | KRAS and NRAS exons 2, 3, 4 | 393 (100) | 393 (100) | EGFR | |
III | Panitumumab | 2nd | Irinotecan | No | 696 | KRAS codons 12, 13, and 61 | 523 (75) | 523 (100) | BRAF, PIK3CA, KRAS/NRAS/BRAF/PIK3CA, EGFR CN, EREG/AREG, EREG, AREG, HER3, MiR 31-3p | |
III | Cetuximab | 1st | Oxaliplatin and fluoropyrimidine | No | 2445 | KRAS codons 12, 13, and 61 | 1949 (80) | 1125 (58) | BRAF, PIK3CA, EGFR, EREG/AREG | |
NORDIC-VII [55] | III | Cetuximab | 1st | FLOX | No | 566 | KRAS and NRAS exons 2, 3, 4 | 457 (81) | 247 (54) | BRAF |
CAPRI-GOIM [56] | II | Cetuximab | 2nd | FOLFOX | No | 153 | KRAS exon 2 | 153 (100) | 153 (100) | KRAS/NRAS/BRAF/PIK3CA |
CALGB 80203 [57] | II | Cetuximab | 1st | FOLFOX or FOLFIRI | No | 238 | KRAS exon 2 | 103 (43) | 55 (53) | EGFR, EREG, AREG, HER2, HER3, HER4 |
III | Cetuximab | 1st | FOLFIRI | Yes | 592 | KRAS and NRAS exons 2, 3, 4 | 515 (87) | 343 (67) | BRAF, MiR 31-3p, MiR-21 | |
CALGB/SWOG 80405 [60] | III | Cetuximab | 1st | mFOLFOX6 or FOLFIRI | Yes | 2326 | KRAS exon 2 | 843 (36) | 600 (71) | BRAF |
PEAK [61] | II | Panitumumab | 1st | mFOLFOX6 | Yes | 285 | KRAS and NRAS exons 2, 3, 4 | 250 (88) | 170 (68) | BRAF |
III | Cetuximab | 1st | Oxaliplatin/irinotecan plus fluorouracil | Yes | 257 | KRAS codons 12, 13, and 61 | 257 (100) | 257 (100) | MiR 31-3p | |
VISNÚ-2 [64] | II | Cetuximab | 1st | FOLFIRI | Yes | 240 | KRAS exons 2 and 3 | 240 (100) | 240 (100) | BRAF/ PIK3CA |